Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Bolt Biotherapeutics Inc (BOLT) USD0.00001

Sell:$22.30 Buy:$22.34 Change: $1.97 (8.10%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Change: $1.97 (8.10%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Change: $1.97 (8.10%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.

Contact details

900 Chesapeake Drive
United States
+1 (650) 6659295

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$870.42 million
Shares in issue:
36.33 million
United States
US dollar

Key personnel

  • Peter Moldt
    Chairman of the Board
  • Randall Schatzman
    Chief Executive Officer, Board Member
  • William Quinn
    Chief Financial Officer
  • David Dornan
    Senior Vice President - Research
  • Michael Alonso
    Vice President - Immunology & Pharmacology, Scientific Co-Founder

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.